SIRI-PGC-1 pathways are recognized as interesting targets for NAFLD because they are involved in lipid metabolism, mitochondrial activation and inflammation in liver [20,21]. The gene discussed is PPARGC1B; the disease is metabolic dysfunction-associated steatotic liver disease.